{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:51:46Z","timestamp":1784170306545,"version":"3.55.0"},"reference-count":29,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["L248022"],"award-info":[{"award-number":["L248022"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-C-015"],"award-info":[{"award-number":["2025-PUMCH-C-015"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-D-001"],"award-info":[{"award-number":["2025-PUMCH-D-001"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary tract cancer (BTC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although immune checkpoint inhibitors combined with chemotherapy have improved patient outcomes, their toxicity remains concerning. This phase II multicenter trial evaluated the efficacy and safety of pembrolizumab plus lenvatinib with a reduced-dose gemcitabine and oxaliplatin (GEMOX) regimen as a first-line therapy for advanced BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>60 patients with unresectable or metastatic BTC were enrolled from five centers in China. Patients received pembrolizumab (200\u2009mg, every 3 weeks), lenvatinib (8 or 12\u2009mg daily), and modified GEMOX (gemcitabine 1000\u2009mg\/m\u00b2 and oxaliplatin 85\u2009mg\/m\u00b2 on day 1 of each 3-week cycle) for 6\u20138 cycles, followed by maintenance with pembrolizumab and lenvatinib. The primary endpoint was objective response rate (ORR), and the secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At a median follow-up of 16.0 months, the ORR (complete response 5.0%, partial response (PR) 50.0%) and disease control rate were 55.0% and 93.3%, respectively. The median PFS and OS were 12.5 months (95% CI 7.93 to 16.3), and 19.5 months (95%\u2009CI 17.97 to not estimable), respectively. Elevated baseline CA19-9 (&gt;37\u2009U\/mL) and carcinoembryonic antigen levels (&gt;5\u2009ng\/mL) were independently associated with poor OS and PFS, respectively. The regimen showed manageable toxicity, with 95% of patients experiencing treatment-emergent adverse events (AEs), mostly grades 1\u20132; grade 3\u20134 AEs occurred in 65% of patients, with no treatment-related deaths. Immune-related AEs occurred in 11.7% of the patients and were predominantly mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pembrolizumab plus lenvatinib with reduced-dose GEMOX demonstrated promising efficacy and a favorable safety profile in advanced BTC, suggesting that chemotherapy de-escalation may optimize the efficacy\u2013toxicity balance. Further randomized studies are warranted to confirm these findings and refine biomarker-based treatment selections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014653","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:45:24Z","timestamp":1770734724000},"page":"e014653","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine\/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06230471","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mingjian","family":"Piao","sequence":"first","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-9501","authenticated-orcid":false,"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[{"name":"Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of PLA General Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of PLA General Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangde","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026062607451529000_14.2.e014653.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2026062607451529000_14.2.e014653.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"2026062607451529000_14.2.e014653.3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"2026062607451529000_14.2.e014653.4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026062607451529000_14.2.e014653.5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026062607451529000_14.2.e014653.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026062607451529000_14.2.e014653.7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000543994","article-title":"Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study","volume":"14","author":"Piao","year":"2025","journal-title":"Liver Cancer"},{"key":"2026062607451529000_14.2.e014653.8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026062607451529000_14.2.e014653.9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013"},{"key":"2026062607451529000_14.2.e014653.10","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00095-5"},{"key":"2026062607451529000_14.2.e014653.11","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"The Lancet"},{"key":"2026062607451529000_14.2.e014653.12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2021.39.3_suppl.321","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","volume":"39","author":"Villanueva","year":"2021","journal-title":"JCO"},{"key":"2026062607451529000_14.2.e014653.13","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026062607451529000_14.2.e014653.14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026062607451529000_14.2.e014653.15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16163","article-title":"Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study","volume":"42","author":"Liu","year":"2024","journal-title":"JCO"},{"key":"2026062607451529000_14.2.e014653.16","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1007\/s12094-025-03916-y","article-title":"SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025)","volume":"27","author":"Macarulla","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"2026062607451529000_14.2.e014653.17","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12659\/MSM.895040","article-title":"Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"21","author":"Liang","year":"2015","journal-title":"Med Sci Monit"},{"key":"2026062607451529000_14.2.e014653.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.05.539","article-title":"394TiP A phase IIIb, single-arm, open-label, multi-center study on durvalumab in combination with gemcitabine-based chemotherapy as first-line treatment for Chinese patients with unresectable biliary tract cancers: TopDouble","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062607451529000_14.2.e014653.19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062607451529000_14.2.e014653.20","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.097","article-title":"Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma","volume":"30","author":"Lin","year":"2019","journal-title":"Ann Oncol"},{"key":"2026062607451529000_14.2.e014653.21","doi-asserted-by":"crossref","unstructured":"Zhang Q , Liu X , Wei S , et al . Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Front Oncol 2021;11. doi:10.3389\/fonc.2021.751391","DOI":"10.3389\/fonc.2021.751391"},{"key":"2026062607451529000_14.2.e014653.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-13814-9","article-title":"Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"2026062607451529000_14.2.e014653.23","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70181","article-title":"A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index","volume":"45","author":"Persano","year":"2025","journal-title":"Liver Int"},{"key":"2026062607451529000_14.2.e014653.24","doi-asserted-by":"crossref","first-page":"114199","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026062607451529000_14.2.e014653.25","doi-asserted-by":"crossref","first-page":"2376429","DOI":"10.1080\/21645515.2024.2376429","article-title":"Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy","volume":"20","author":"Ma","year":"2024","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"2026062607451529000_14.2.e014653.26","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2541314","article-title":"Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection","volume":"57","author":"Abaydulla","year":"2025","journal-title":"Ann Med"},{"key":"2026062607451529000_14.2.e014653.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-025-03639-8","article-title":"Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET\/CT, DNA mutation, and CA199","volume":"25","author":"Qi","year":"2025","journal-title":"Cancer Cell Int"},{"key":"2026062607451529000_14.2.e014653.28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071243","article-title":"Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy","volume":"17","author":"Nishida","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026062607451529000_14.2.e014653.29","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/CM9.0000000000003130","article-title":"Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between CA19-9 (+) and CA19-9 (\u2212) PDAC","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin Med J"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:33Z","timestamp":1782485133000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-014653"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014653","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}